These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29309589)

  • 1. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD; Makras P; Pikilidou M; Tournis S; Makris K; Bisbinas I; Tsave O; Yovos JG; Yavropoulou MP
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1206-1213. PubMed ID: 29309589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis.
    Yavropoulou MP; Anastasilakis AD; Makras P; Papatheodorou A; Rauner M; Hofbauer LC; Tsourdi E
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32521543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
    Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriparatide and denosumab combination therapy and skeletal metabolism.
    Idolazzi L; Rossini M; Viapiana O; Braga V; Fassio A; Benini C; Kunnathully V; Adami S; Gatti D
    Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of plasma microRNA-21 expression and bone turnover markers in postmenopausal women.
    Perksanusak T; Panyakhamlerd K; Hirankarn N; Suwan A; Vasuratna A; Taechakraichana N
    Climacteric; 2018 Dec; 21(6):581-585. PubMed ID: 30232913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
    Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.
    Cosman F; Lane NE; Bolognese MA; Zanchetta JR; Garcia-Hernandez PA; Sees K; Matriano JA; Gaumer K; Daddona PE
    J Clin Endocrinol Metab; 2010 Jan; 95(1):151-8. PubMed ID: 19858319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
    Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.
    Tsai JN; Burnett-Bowie SM; Lee H; Leder BZ
    Bone; 2017 Feb; 95():20-25. PubMed ID: 27840301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Rauner M; Sonnleitner L; Hawa G; Tsourdi E; Yavropoulou MP; Missbichler A; Terpos E
    J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):253-257. PubMed ID: 31475931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.